Xenon net loss widens 30.7% to $110.74 million in Q2 FY26
Reuters2026/08/06 20:07- Xenon posted a Q2 net loss of USD 110.7 million, widening from USD 84.7 million a year earlier.
- RD costs rose to USD 99.2 million from USD 75 million, driven by Phase 3 azetukalner programs, Phase 1 pain studies, manufacturing, headcount.
- GA spending climbed to USD 23.9 million from USD 19.2 million, on higher headcount plus professional and consulting fees.
- Other income increased to USD 11.8 million from USD 8.9 million, reflecting higher interest income.
- Cash, cash equivalents, marketable securities totaled USD 1.25 billion; NDA for azetukalner in focal onset seizures remains on track for Q3 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
TotalEnergies (TTE.US) partners with Mistral: 100 million euros bet on AI exploration, European "sovereign AI" implemented in core energy scenarios
TotalEnergies (TTE.US) will collaborate with French artificial intelligence startup Mistral AI to leverage AI technology to enhance its oil and gas exploration capabilities and extend the lifespan of existing oil fields.
Policy Environment Turning More Challenging for Fed -- Market Talk
Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Tuesday; iQIYI, CrowdStrike to Open Lower
X-Energy, Centrica, Advance UK Small Modular Reactor Project
Crypto prices
More
